Investigating taste responses in obese individuals before and after weight loss surgery
Official title: Taste Physiology in Obese Volunteers Before and After Bariatric Surgery
Run by University Hospital, Basel, Switzerland · NCT02902198 · Data updated 2026-11-12
This study is trying to see how weight loss surgery changes the way morbidly obese people taste food and how their brains respond to it.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 16 (estimated) |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Status | Recruiting |
| Started | December 2014 |
| Main results expected | December 2026 |
| Study ends | December 2027 |
| Registry record updated | April 3, 2025 |
| Trial ID | NCT02902198 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are morbidly obese individuals with a BMI of at least 35 kg/m2 who are scheduled for bariatric surgery.
✕Probably not a fit
Patients with cardiovascular disease or neurologic/psychiatric disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to explore the neuro-anatomical responses to gastrointestinal taste stimulation in morbidly obese individuals by using functional MRI. Participants will receive intragastric administration of glucose, monosodium glutamate, chloroquine, and a placebo, followed by brain imaging before and three months after undergoing bariatric surgery. The goal is to understand how bariatric surgery affects taste perception and related brain activity in obese patients.
Why it matters
Potential benefit: If successful, this study could enhance understanding of taste physiology in obesity and improve post-surgical outcomes for patients.
How similar studies have gone: While this approach is innovative, similar studies exploring taste physiology in obesity have shown promising results, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * morbidly obese patients (BMI min 35kg/m2) scheduled for bariatric surgery * right handed Exclusion Criteria: * cardiovascular disease * neurologic/psychiatric disorders
Where it's running
-
University Hopital Basel
Basel, Switzerland Recruiting
Study contacts
- Study coordinator: Bettina Wölnerhanssen, Dr
- Email: bettina.woelnerhanssen@usb.ch
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.